Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Consulting agrmnt
AKCEA THERAPEUTICS, INC. (AKCA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2020 8-K Quarterly results
08/31/2020 8-K Quarterly results
08/04/2020 8-K Quarterly results
07/09/2020 8-K Quarterly results
06/19/2020 8-K Quarterly results
05/18/2020 8-K Appointed a new director
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 18, 2020 Akcea Therapeutics, Inc. Delaware 001-38137 47-2608175 22 Boston Wharf Road 9th Floor Boston, MA 02210 Registrant's Telephone Number, Including Area Code: 207-0202 Not Applicable Title of each class Trading Symbol Name of each exchange on which registered Common stock AKCA NASDAQ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Ac...",
"Michael D. Price Offer Letter",
"Michael D. Price Severance Benefit Agreement",
"Akcea Announces Appointment of New Chief Financial Officer"
05/05/2020 8-K Quarterly results
04/29/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Severance Benefit Agreement between the Company and Robert Dolski",
"Severance Benefit Agreement between the Company and Robert Dolski"
04/09/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Separation Agreement between the Company and Michael MacLean entered into on April 4, 2020",
"Separation Agreement between the Company and Michael MacLean entered into on April 4, 2020"
03/24/2020 8-K Quarterly results
03/20/2020 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 16, 2020 Akcea Therapeutics, Inc. Delaware 001-38137 47-2608175 22 Boston Wharf Road 9th Floor Boston, MA 02210 Registrant's Telephone Number, Including Area Code: 207-0202 Not Applicable Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common stock AKCA NASDAQ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Solici...",
"Retention Agreement between Louis St. L. O'Dea and the Company",
"Severance Benefit Agreement between Louis St. L. O'Dea and the Company",
"Global Option Agreement between Louis St. L. O'Dea and the Company"
03/11/2020 8-K Quarterly results
03/04/2020 8-K Quarterly results
02/25/2020 8-K Quarterly results
02/13/2020 8-K Quarterly results
01/28/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : January 28, 2020 Akcea Therapeutics, Inc. Delaware 001-38137 47-2608175 22 Boston Wharf Road 9th Floor Boston, MA 02210 Registrant's Telephone Number, Including Area Code: 207-0202 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ ...",
"Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-L Rx"
01/22/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : January 22, 2020 Akcea Therapeutics, Inc. Delaware 001-38137 47-2608175 22 Boston Wharf Road 9th Floor Boston, MA 02210 Registrant's Telephone Number, Including Area Code: 207-0202 Not Applicable Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common stock AKCA NASDAQ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soli...",
"Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-LRX"
01/10/2020 8-K Entry into a Material Definitive Agreement
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : January 9, 2020 Akcea Therapeutics, Inc. Delaware 001-38137 47-2608175 22 Boston Wharf Road 9th Floor Boston, MA 02210 Registrant's Telephone Number, Including Area Code: 207-0202 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ P..."
01/06/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/19/2019 8-K Quarterly results
12/16/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 13, 2019 Akcea Therapeutics, Inc. Delaware 001-38137 47-2608175 22 Boston Wharf Road 9th Floor Boston, MA 02210 Registrant's Telephone Number, Including Area Code: 207-0202 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐...",
"Akcea Therapeutics Announces New Appointments to its Board of Directors"
12/04/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 2, 2019 Akcea Therapeutics, Inc. Delaware 001-38137 47-2608175 22 Boston Wharf Road 9th Floor Boston, MA 02210 Registrant's Telephone Number, Including Area Code: 207-0202 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ ...",
"Alex Howarth Offer Letter",
"Alex Howarth Severance Benefit Agreement",
"Akcea Announces Appointment of New Chief Operating Officer"
11/05/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 5, 2019 Akcea Therapeutics, Inc. Delaware 001-38137 47-2608175 22 Boston Wharf Road 9th Floor Boston, MA 02210 Registrant's Telephone Number, Including Area Code: 207-0202 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ ...",
"Akcea Reports Financial Results and Highlights for Third Quarter 2019"
10/23/2019 8-K Quarterly results
10/17/2019 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : October 11, 2019 Akcea Therapeutics, Inc. Delaware 001-38137 47-2608175 22 Boston Wharf Road 9th Floor Boston, MA 02210 Registrant's Telephone Number, Including Area Code: 207-0202 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ ...",
"Letter Agreement between Mike MacLean and the Company"
10/08/2019 8-K Quarterly results
09/23/2019 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : September 18, 2019 Akcea Therapeutics, Inc. Delaware 001-38137 47-2608175 22 Boston Wharf Road 9th Floor Boston, MA 02210 Registrant's Telephone Number, Including Area Code: 207-0202 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) &#9744...",
"Akcea Damien McDevitt Offer Letter",
"Akcea - Severance Agreement_McDevitt Damien",
"Akcea Announces CEO Transition and Elects Two New Board Members"
08/06/2019 8-K Quarterly results
05/08/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 8, 2019 Akcea Therapeutics, Inc. Delaware 001-38137 47-2608175 22 Boston Wharf Road 9th Floor Boston, MA 02210 Registrant's Telephone Number, Including Area Code: 207-0202 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-c...",
"Akcea Reports Financial Results and Highlights for First Quarter 2019"
04/26/2019 8-K Submission of Matters to a Vote of Security Holders
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : April 24, 2019 Akcea Therapeutics, Inc. Delaware 001-38137 47-2608175 22 Boston Wharf Road 9th Floor Boston, Massachusetts 02210 Registrant's telephone number, including area code: 207-0202 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-co..."
02/26/2019 8-K Quarterly results
02/25/2019 8-K Quarterly results
11/23/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Akcea Therapeutics, Inc. 2015 Equity Incentive Plan, as amended",
"Akcea Therapeutics, Inc. 2015 Equity Incentive Plan, as amended"
11/05/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 5, 2018 Akcea Therapeutics, Inc. Delaware 001-38137 47-2608175 22 Boston Wharf Road 9th Floor Boston, Massachusetts 02210 Registrant's telephone number, including area code: 207-0202 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-...",
"Akcea Reports Financial Results and Highlights for Third Quarter 2018"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy